Group 1 - The company reported a revenue of 6.51 billion yuan for the year 2024, with a first-quarter revenue of 2.36 billion yuan in 2025, reflecting a year-on-year decline of 6.5% [1] - Despite challenges such as inventory adjustments and impairment provisions, the company maintained a high level of R&D investment at 908 million yuan, accounting for 13.94% of revenue, demonstrating a commitment to innovation [1] - The company is positioned as a leader in the traditional Chinese medicine sector, with a strong patent barrier and product matrix, which is expected to support future performance as new drugs are launched [1] Group 2 - The company has made significant progress in its innovative drug pipeline, with two new Class 1 traditional Chinese medicine drugs entering the application stage and several others in clinical trials [2] - The health sector expansion includes over 150 products based on the "meridian-nourishing" concept, and the approval of proprietary health food formulas further enriches the product line [2] - The company is accelerating its internationalization through 13 ANDA approvals in the U.S. and registrations in 53 countries, leveraging policies favoring traditional Chinese medicine and expanding its CDMO business [2] Group 3 - The traditional Chinese medicine industry is benefiting from favorable policies and market demand, particularly in chronic disease management due to an aging population [3] - The company's cardiovascular products accounted for over 50% of revenue in 2024, with key products maintaining a strong market share in public hospitals [3] - The company has established a competitive edge with 17 patented traditional Chinese medicines and 11 products covered by medical insurance, positioning it to benefit from industry consolidation [3]

Core Insights - Yiling Pharmaceutical has shown significant improvement in its financial performance, particularly in cash flow management and profitability, despite facing challenges in 2024 [1][3][6] - The company has successfully returned to a growth trajectory in Q1 2025, with notable increases in net profit and operating income [2][6] Financial Performance - In 2024, Yiling Pharmaceutical achieved operating revenue of 6.513 billion yuan, but faced challenges due to product expiration, rising raw material costs, and high R&D investments, impacting net profit [2] - In Q1 2025, the company reported operating revenue of 2.358 billion yuan and a net profit of 326 million yuan, marking a year-on-year increase of 7.25% [2] - The gross profit margin improved to 53.82%, up 2.34 percentage points, while the net profit margin rose to 13.82%, an increase of 1.85 percentage points [2] Cash Flow and Financial Health - The net cash flow from operating activities reached 611 million yuan in 2024, a year-on-year increase of approximately 293% [3] - In Q1 2025, the operating cash flow was 340 million yuan, nearly double the net profit for the same period [3] - Accounts receivable decreased significantly by 50% to 1.225 billion yuan, indicating effective measures in cash collection and asset quality improvement [3] R&D Investment and Innovation - Yiling Pharmaceutical's R&D investment in 2024 was 908 million yuan, accounting for 13.94% of operating revenue, positioning it among the top in the industry [4] - The company holds 17 patented traditional Chinese medicines and has received numerous national and provincial awards for its research efforts [4][5] - Ongoing R&D projects include two traditional Chinese medicines submitted for production and six in clinical stages, supported by successful completion of five evidence-based medical research projects [5] Marketing and Sales Strategy - The company has developed a multi-channel marketing strategy, enhancing collaboration with traditional medical institutions and expanding online sales through e-commerce platforms [6] - Yiling Pharmaceutical's product, Lianhua Qingwen Granules/Capsules, ranked first in the Chinese public medical market for cold medications, with a market share of 24.36% [6] - The marketing strategy focuses on brand building and community engagement to enhance brand recognition and consumer loyalty [6] Future Outlook - Yiling Pharmaceutical is expected to leverage its comprehensive advantages in R&D, production, and sales to continue innovating and contributing to public health [7]

以岭药业 20250429 摘要 • 以岭药业 2025 年一季度营收 23.58 亿元，同比下降 6.5%，归母净利润 3.26 亿元，同比增长 7.25%，经营性净现金流 3.4 亿元，同比增长 190%。应收账款周转天数同比下降 35 天，经营质量初步提升。 • 连花清瘟产品一季度销售同比增长近 30%，心脑血管处方药受政策影响有 所下滑，但预计二季度将逐步恢复性增长。二线品种如静神胶囊、复方丹 参片等开户工作稳步推进，OTC 品种八子补肾胶囊加大推广力度。 • 健康科技板块重点推广蓝帽子保健食品及功能性植物饮料，怡梦饮料单品 销售超 1.2 亿，调节血糖饮料精力旺销售额超 5,000 万，市场前景良好。 • 公司研发方面，治疗糖尿病视网膜病变的明目胶囊进入医保，治疗过敏性 鼻炎的芪芳鼻通片获批上市，六个品种处于临床阶段，小儿连花清瘟颗粒 处于三期临床。五项循证医学研究成果发表在国际顶刊。 • 化学生物板块有四个创新药进入临床阶段，多个一类创新药处于临床前验 证阶段，百乐宁已报产，SY0,206 片用于急性髓性白血病治疗已进入三期 临床研究。 Q&A 2024 年以岭药业的营业收入和净利润情况如何？ 2 ...

业绩变动，以岭药业表示，主要系报告期内部分呼吸系统产品临近有效期，公司冲减相关产品销售收 入，并对临近有效期存货计提了资产减值损失，加之报告期内收入减少、原材料价格上涨导致毛利率下 降、研发保持较高投入等原因。 2024年，面对医药行业的竞争压力，以岭药业（002603）管理层坚持"规范、专业、健康、持续、跨 越"方针，以"品牌致胜、形成规模、实现目标、创造利润"价值文化为指导，以市场为导向，以效益为 中心，以管理为保障，持续规范和优化业务流程，全面加强预算管理和成本控制，建立全链条的成本控 制体系，积极推进阿米巴经营，保持研发投入，提高运营效率。 24年度营收65.13亿元经营性净现金流大幅改善 数据显示，2024年1-12月，以岭药业实现营业收入65.13亿元，同比下降36.88%；归母净利润为-7.25亿 元，同比下降153.57%。 以岭药业始终将研发作为核心竞争力，报告期内，公司2024年研发费用保持持续增长状态，达到9.08亿 元，占营收比重提升至13.94%，持续夯实中医药创新领军地位。这一巨额投入彰显了公司对于科技创 新的高度重视和坚定决心。公司围绕心脑血管、呼吸系统、内分泌等核心领域，构建起 ...

特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 3、董事会关于计提资产减值准备合理性的说明。 石家庄以岭药业股份有限公司 董事会 石家庄以岭药业股份有限公司 2025年4月29日 证券代码：002603 证券简称：以岭药业 公告编号：2025-014 关于变更会计政策的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 石家庄以岭药业股份有限公司根据中华人民共和国财政部（以下简称"财政部"）颁布的《企业数据资源 相关会计处理暂行规定》（财会〔2023〕11号）、《关于印发〈企业会计准则解释第17号〉的通知》 （财会〔2023〕21号，以下简称"《准则解释第17号》"）以及《关于印发〈企业会计准则解释第18号〉 的通知》（财会〔2024〕24号，以下简称"《准则解释第18号》"）的要求变更会计政策。本次变更会计 政策是公司依据法律法规和国家统一会计准则要求进行变更，不会对公司财务状况、经营成果和现金流 量产生重大影响。 现将变更情况公告如下： 一、会计政策变更概述 （一）变更的原因 2023年8月，财政部发布了《企业数据资源相关会计处理暂行规定》 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002603 证券简称：以岭药业 公告编号：2025-008 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以2024年12月31日总股本1,670,705,376股为基数，向全 体股东每10股派发现金红利0元（含税），送红股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要业务情况 公司的主营业务是专利创新中药的研发、生产和销售。在专注创新中药研发的同时，公司积极布局化生 药和健康产业，构建了专利中药、化生药、健康产业协同发展、相互促进的医药健康产业格局。 1、在专利中药板块，公司形成了独具优势的以络 ...

石家庄以岭药业股份有限公司 证券代码：002603 证券简称：以岭药业 公告编号：2025-020 关于化药创新药"G201-Na 胶囊"药物临床试验申请获 得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日收到 国家药品监督管理局核准签发的《受理通知书》，现将相关情况公告如下： 一、临床试验申请主要内容 药物名称：G201-Na 胶囊 受 理 号：CXHL2500424，CXHL2500425 受理日期：2025 年 04 月 29 日 剂 型：胶囊剂 适 应 症：辅助生殖，用于控制性超促排卵治疗的患者，防止提前排卵。 申请事项：境内生产药品注册临床试验 申 请 人：石家庄以岭药业股份有限公司 通知书意见：自受理之日起 60 日内，未收到药审中心否定或质疑意见的， 申请人可以按照提交的方案开展临床试验。 二、G201-Na 胶囊相关情况 G201-Na胶囊项目是公司自主研发、具有独立知识产权的1类化学新药。本 品为小分子促性腺激素释放激素（GnRH）受体拮抗剂。可以阻 ...

Group 1: Product Development and Clinical Trials - The company plans to submit 1-2 new products for approval each year, with recent submissions including products for chronic cholecystitis and rheumatoid arthritis [2] - Currently, there are 6 products in clinical stages, with one in Phase III for treating children's colds and five in Phase II for various conditions [2][3] - The company has completed the registration of 536 products and has a 90% average registration rate across 14 provinces for formula granules [5] Group 2: Health Industry Progress - The company has developed a comprehensive health product system integrating traditional Chinese medicine with modern technology, focusing on health management and product development [4] - Key promoted products include health foods and functional beverages, with significant revenue growth expected in 2024 [4] Group 3: Sales Strategies and Market Expansion - The company is enhancing sales of its BaZi products through retail, e-commerce, and partnerships, aiming to build brand recognition and customer loyalty [6][7] - The company has seen rapid growth in BaZi product sales in Q1 2025, with strategies to improve customer adherence and long-term management [6][7] Group 4: International Market Development - The company aims to enhance the international influence of traditional Chinese medicine by promoting its unique theories and establishing academic collaborations globally [11][12] - It has established over 130 professional committees abroad and has received approvals for its patented traditional medicines in over 50 countries [12] Group 5: OTC Product Strategy - The company’s Lianhua Qingke product transitioned to OTC status in November 2023, which is expected to create new marketing opportunities and enhance sales through flexible promotion strategies [13]

以岭药业于4月28日晚间披露了2024年年报，因部分呼吸类产品临近有效期冲减收入和存货减值升提等原因 导致全年净利润由盈转亏，该情况具有阶段性和特殊性。 不过，年报显示，以岭药业依然保持了较高的研发投入。2024年全年，公司研发投入超过9亿元，占营业收 入比重为13.94%，处于同行业领先水平。 以岭药业主营业务是专利创新中药的研发、生产和销售，聚焦于心脑血管、呼吸、内分泌、神经、消化、免 疫、泌尿等核心疾病领域，其中心脑血管和呼吸系统药物是其最主要的收入来源。 高研发投入为长期增长蓄力 长期以来，依托独具优势的络病理论，以岭药业在创新中药方面有着强大的研发能力，成为其独特的技术优 势所在。 从公立医疗端表现看，据米内网数据统计，2024年上半年中国公立医疗市场中成药感冒用药中，连花清瘟的 市场份额为24.36%，位列第一。 参松养心胶囊、通心络胶囊和芪苈强心胶囊三大创新专利中药作为以岭药业的心脑血管领域核心产品，公立 医疗市场领域的合计份额在2024年上半年时达到17.69%，分别位居2024年上半年中国公立医疗市场中成药心 血管疾病内服用药TOP10的第四、五、六位。糖尿病中成药方面，津力达颗粒在院内市场 ...